ResApp Health Limited (ASX: RAP), in partnership with UniQuest (the main commercialisation company of The University of Queensland), is pleased to announce that it has shipped smartphones to a leading global humanitarian organisation under the terms of a non-binding memorandum of understanding to field-test ResApp’s smartphone-based respiratory disease diagnostic tool in the developing world.
According to the World Health Organisation, pneumonia kills more than 950,000 children under five every year, the vast majority in South Asia and sub-Saharan Africa. Many of these deaths are caused by delays in diagnosis due to the lack of high-quality medical care in these regions.
The smartphones include ResApp’s propriety respiratory diagnostic software to enable medical professionals to test the usability of the company’s technology in the field. The field evaluation is a precursor to a large-scale multi-country study of the system’s ability to accurately diagnose respiratory disease.
Tony Keating, CEO and Managing Director of ResApp said, “I am excited to be working with this prestigious humanitarian organisation to not only perform a field trial that will generate additional clinical evidence, but also to garner an in-depth understanding of the local conditions so that we can optimise a product for essential medical personnel working in very challenging environments. We look forward to collaborating closely with this leading humanitarian organisation as we make solid progress in delivering a tool that could significantly reduce the burden of pneumonia in the developing world.”
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 12, 100 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.